Difference between revisions of "Serplulimab (Hansizhuang)"
Jump to navigation
Jump to search
m (→Also known as) |
|||
| Line 28: | Line 28: | ||
[[Category:Malignant solid neoplasm, MSI-H or dMMR medications]] | [[Category:Malignant solid neoplasm, MSI-H or dMMR medications]] | ||
| + | [[Category:Non-small cell lung cancer, squamous medications]] | ||
[[Category:Small cell lung cancer medications]] | [[Category:Small cell lung cancer medications]] | ||
[[Category:NMPA approved in 2022]] | [[Category:NMPA approved in 2022]] | ||
Latest revision as of 01:17, 23 May 2024
General information
Class/mechanism: PD-1 receptor antibody.
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Toxicity management
Diseases for which it is used
History of changes in NMPA indication
- 2022-03-25: Initial approval for the treatment of adult patients with advanced unresectable or metastatic MSI-H (Microsatellite Instability-High) solid tumors that have failed to respond to previous standard treatments. (Based on HLX10-010-MSI201)
- 2022-11-01: Approved in combination with carboplatin and albumin-bound paclitaxel for the first-line treatment of unresectable locally advanced or metastatic squamous non-small cell lung cancer (sqNSCLC). (Based on ASTRUM-004)
- 2023-01-18: Approved for ES-SCLC in combination with carboplatin & etoposide. (Based on ASTRUM-005)
Also known as
- Code name: HLX-10
- Brand name: Hansizhuang